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Donor safety in living liver donation is of paramount importance; however, information on long-term outcomes is limited by
incomplete follow-up. We sought to ascertain factors that predicted postdonation follow-up in 456 living liver donors in the
Adult-to-Adult Living Donor Liver Transplantation Cohort Study. Completed donor follow-up was defined as physical, phone,
or laboratory contact at a given time point. Univariate and multivariate mixed effects logistic regression models, using donor
and recipient demographic and clinical data and donor quality-of-life data, were developed to predict completed follow-up.
Ninety percent of the donors completed their follow-up in the first 3 months, and 83% completed their follow-up at year 1;
rates of completed follow-up ranged from 57% to 72% in years 2 to 7 and from 41% to 56% in years 8 to 10. The probabil-
ity of completed follow-up in the first year was higher for white donors [odds ratio (OR)5 3.27, 95% confidence interval
(CI)5 1.25-8.58] but lower for donors whose recipients had hepatitis C virus or hepatocellular carcinoma (OR50.34, 95%
CI5 0.17-0.69). After the first year, an older age at donation predicted more complete follow-up. There were significant cen-
ter differences at all time points (OR range5 0.29-10.11), with center variability in both returns for in-center visits and the
use of phone/long-distance visits. Donor follow-up in the first year after donation was excellent but decreased with time. Pre-
dictors of follow-up varied with the time since donation. In conclusion, adapting best center practices (enhanced through the
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Donor safety is of paramount importance in assessing
the success of living donor liver transplantation
(LDLT). To date, most data have focused on short-
term outcomes, including death and surgical compli-
cations such as bile leakage.1-4 A wide range of
complication rates have been reported for donors after
LDLT. Overall, reported complication rates have
ranged from 0% to 67%, with an overall crude compli-
cation rate in a meta-analysis and the large National
Institutes of Health–funded Adult-to-Adult Living
Donor Liver Transplantation Cohort Study (A2ALL)
experience of approximately 38%.5-7 Studies assess-
ing donor health-related quality of life (HRQOL) after
LDLT have also yielded variable findings, although
most have demonstrated that HRQOL (assessed with
generic instruments not specific to LDLT) is at or
above US norms.8 These studies also have consis-
tently found that nearly all donors state that they
would donate again, regardless of recipient out-
comes.8-12 Nevertheless, 71% of donors have reported
abdominal symptoms several months after the opera-
tion that they attributed to the donation surgery,10
and it is clear that psychological distress is relatively
common in both liver and kidney donors.13
Longer term follow-up is particularly important and
may identify areas that may be sources of stress and
concern to donors, including finances14 and the inci-
dence of long-term psychiatric disturbances.15 To
accurately determine the effects of donation on living
liver donors, it is important for transplant centers to
maintain contact with donors over the long-term. Cur-
rently, 2 years’ follow-up is mandated for the United
Network for Organ Sharing (UNOS) reporting require-
ments, but this may inadequately capture the impact
on long-term donor HRQOL and health. In order to
acquire these data and ensure continued donor
follow-up and complete data, state-of-the art methods
need to be implemented. These methods have not
been implemented in most prior studies. One of the
barriers to obtaining high-quality long-term data from
donors is the variable practice patterns of centers fol-
lowing donors after living donation with respect to the
frequency and duration of visits after LDLT.16 In addi-
tion, years after LDLT, donors may be lost to follow-
up or difficult to contact because of a real or perceived
lack of need for medical care, insurance and financial
barriers, or a lack of access to care. The issues that
determine whether donors will or will not pursue
long-term follow-up are likely multifactorial and
include donor, recipient, and center factors, but these
issues have not been systematically studied.
Using the multicenter A2ALL cohort study, we
investigated the factors associated with donor contact
with transplant centers for the purpose of A2ALL
study follow-up. The objective of this study was to
assess the characteristics that make donors more
likely to maintain contact with their transplant cen-
ters with the goal of improving donor follow-up in
future clinical care as well as research settings. This
is particularly timely because UNOS is considering
mandating new thresholds for complete follow-up for
living donors in the future.
PATIENTS AND METHODS
Data Collection
The A2ALL study collected prospective data on living
liver donors and their recipients enrolled at 9 US
transplant centers between 2004 and 2009. Prospec-
tive living liver donors as well as previous living liver
donors who donated after January 1, 1998 were eligi-
ble for enrollment. According to the clinical A2ALL
protocol, donors were scheduled to return to the
transplant center for postdonation follow-up at 1
week, 1 month, 3 months, 12 months, and annually
thereafter. For donors who enrolled after donation,
protocol study visits began at the corresponding post-
donation time point; thus, the expected number of
visits per donor varied according to when they were
enrolled. The duration of A2ALL follow-up was beyond
the standard clinical follow-up protocol for donors at
most centers. When donors were unable to return to
the transplant center for a study visit, coordinators
attempted to contact subjects via phone and mail,
and donors were asked to send local laboratory
results to the transplant center. These methods of
remote follow-up were similar to methods of follow-up
allowable for the Organ Procurement and Transplan-
tation Network (OPTN) data collection.
For this analysis, completed follow-up was defined
as the collection of any data on the donor’s status by
any method since the last prospective assessment.
The information could be obtained during a clinical
visit or by telephone, e-mail, post mail, or other
means when a visit was not possible. Further catego-
rization was performed according to whether data
were collected during an actual clinic visit or with
other methods only. The expected follow-up visit dates
were calculated from the transplant date, and visit
window endpoints were halfway between adjacent
expected visit dates. Expected visits were included in
the analysis only if the donor had consented to the
study before the start of the window and had not
withdrawn consent or died before the end of the win-
dow. This rule was followed regardless of whether or
not a visit occurred because it was too difficult to
determine whether a visit should have been expected
if the subject had not been enrolled for the entire win-
dow. For example, there were 4 protocol visits in the
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first year (at 1 week, 1 month, 3 months, and 1 year);
however, a donor who enrolled in the month 1 window
would have only 2 expected visits in the first year
because of the timing of the enrollment.
For each donor, recipient information, including
diagnoses and dates of retransplantation and death,
was obtained from the A2ALL recipient database.
When such information was not available, this study
used data from the Scientific Registry of Transplant
Recipients (SRTR). The SRTR data system includes
data on all donors, wait-listed candidates, and trans-
plant recipients in the United States; these data are
submitted by the members of OPTN and have been
described elsewhere. The Health Resources and Serv-
ices Administration (US Department of Health and
Human Services) provides oversight for the activities
of the OPTN and SRTR contractors.
HRQOL surveys, including the Short Form 36 (SF-
36; version 2), were administered to donors before
donation. The SF-36 was additionally administered 3
and 12 months after donation and annually there-
after. Donors who had enrolled after donation were
administered the SF-36 at the first postdonation
study visit after their enrollment. The HRQOL surveys
were administered in several formats (on tablet com-
puters, via paper forms either by mail or at the clini-
cal center, by telephone, or with a Web-based format)
to maximize responses. The Mental Component Score
(MCS) and the Physical Component Score (PCS), cal-
culated from the SF-36 survey, were standardized to
the US population distribution [average550, stand-
ard deviation (SD)510].
The study was approved by the institutional review
boards and privacy boards of the University of Michi-
gan Data Coordinating Center and each of the 9 par-
ticipating transplant centers. All subjects provided
written informed consent for this study.
Statistical Analysis
Descriptive statistics included means, SDs, and
proportions. The means, SDs, and interquartile
ranges of the numbers of expected and completed
follow-up visits were calculated for the visits from
the first week through the first year, for every sub-
sequent 3-year period, and overall. The proportion
of donors who completed follow-up at each postdo-
nation study time point was graphed with standard
error bars based on the binomial distribution along
with center-specific proportions at each time point
for which a given center had at least 5 expected
visits. The proportion of donors who completed any
type of follow-up (including in-person, phone, and
e-mail contact) and the proportion who completed
follow-up clinic visits at the transplant center were
also graphed by transplant center. Finally, centers
were divided into 2 groups: those that had at least
80% follow-up and those with <80% follow-up. The
percentages of follow-up completed at the clinic
and by other means were graphed by time point for
these 2 groups.
The probability of completed follow-up was modeled
with multivariate repeated measures logistic regres-
sion to account for multiple measurements of the
same subject over time. Completed follow-up through
the first year (month 1, month 3, and year 1) was
modeled separately from completed follow-up at year
2 and subsequent annual follow-up (through year 10)
because different covariates were important in the
earlier time periods versus the later time periods.
Week 1 was not included in the models because every
subject had completed follow-up at this time. The 2
highest performing centers were combined because of
small cell counts. These centers were both in large
cities with ethnically diverse populations. The within-
subject correlation across study visits was modeled
with a 4-parameter Toeplitz covariance structure.16
Variables considered for inclusion included the follow-
ing: donor demographics (sex, ethnicity, race, age at
donation, and education level), relationship with the
recipient (spouse, immediate family, or other), surro-
gate for the distance from the transplant center (living
in the same state or a state contiguous to the state of
the transplant center versus living in a more distant
state; only the donor’s state of residence—not the dis-
tance from the transplant center—was collected),
indicator variable for each transplant center, trans-
plant center volume (3-year average for the visit year
and the 2 prior years), complications in the first year
after donation (Clavien grade 2 or higher or Clavien
grade 3 or higher), recipient diagnosis [hepatitis C
virus (HCV) or hepatocellular carcinoma (HCC),
alcohol-related diagnosis, cholestatic cirrhosis, or
other], recipient outcomes (graft loss or death in the
prior year or in any previous year), and number of
years from donation. To estimate the amount of varia-
tion in follow-up explained by center effects, we sepa-
rately modeled the month 3, year 1, and year 2 time
points with logistic regression and compared the gen-
eralized R2 statistic between models with and without
center effects.
Seven of the 9 participating centers (those whose
participation continued in the second phase of A2ALL)
submitted information on their standard-of-care fol-
low-up schedule for living liver donors. Indicators for
whether follow-up was required at the transplant cen-
ter beyond 1 month and 2 years after donation were
also tested in the models. For the subset of donors for
whom HRQOL data were available, the PCS and the
MCS from the SF-36 were tested as potential time-
dependent predictors of completed follow-up in a sepa-
rate logistic regression model. Models were fit with PCS
and MCS values from the previous visit to predict com-
pleted follow-up at the next visit. In these models,
because of the smaller number of donors with HRQOL
data and the limited number of usable visits per donor,
the within-subject correlation was modeled with the
single-parameter compound symmetry covariance
structure.16 Variables with P values less than 0.1 were
considered significant for all previously described mod-
els from above. All analyses were conducted with SAS
9.2 software (SAS Institute, Inc., Cary, NC).
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RESULTS
There were 456 donors included in the analysis, with
scheduled postdonation study visits ranging from 1
week to 10 years after donation. At donation, the
mean age was 38 years (range518-63 years). The
majority was female and white, had education beyond
high school, and donated to a spouse or immediate
family member (Table 1). The leading diagnoses of the
recipients of the living donor grafts included HCV or
HCC (45%) and cholestatic cirrhosis (29%). Graft fail-
ure (defined as retransplantation or death) was
observed in 25% of the recipients during follow-up.
Complications occurred in 27% of the donors in the
first year after donation, and 19% had Clavien grade
2 or higher complications during this time period.
Three centers comprising 176 donors had at least
80% follow-up (high–follow-up centers), and the
remaining 6 centers comprising 280 donors had less
than 80% follow-up (low–follow-up centers) (Tables
1 and 2). We chose 80% as the cutoff because it is
suggested in the OPTN guidance document for
living donor follow-up.17 Donors at high–follow-up
centers were significantly younger than those at low–
follow-up centers (mean age: 36.0 versus 39.2 years,
P50.001), and they had fewer grade 2 or higher
complications in the first year (14% versus 22%,
P50.04).
TABLE 1. Characteristics of Donors Who Donated at Centers With <80% or 80% Follow-Up
Overall (n5456)
<80% Follow-Up
(n5280)
80% Follow-Up
(n5176)
n or
Mean
% or SD
(Range)
n or
Mean
% or SD
(Range)
n or
Mean
% or SD
(Range)
P
Value*
Age at donation (years) 38.0 10.3 (18-63) 39.2 10.4 (18-63) 36.0 9.9 (19-55) 0.001
Sex 0.90
Male 216 47% 132 47% 84 48%
Female 240 53% 148 53% 92 52%
Race 0.07
Nonwhite 54 12% 27 10% 27 15%
White 402 88% 253 90% 149 85%
Ethnicity 0.05
Non-Hispanic/non-Latino 389 85% 246 88% 143 81%
Hispanic/Latino 67 15% 34 12% 33 19%
Total education 0.68
Grade school or high school 96 21% 59 21% 37 21%
Attended college/technical school 122 27% 78 28% 44 25%
Associate, bachelor, or
postcollege graduate degree
183 40% 122 44% 61 35%
Unknown 55 12% 21 8% 34 19%
Relationship with recipient 0.09
Spouse 53 12% 39 14% 14 8%
Immediate family (parent,
child, or full sibling)
251 55% 145 52% 106 60%
Other 152 33% 96 34% 56 32%
Distance from center 0.87
Within 1 US state of transplant center 367 80% 226 81% 141 80%
>1 US state from transplant center 89 20% 54 19% 35 20%
Complication in first year 124 27% 83 30% 41 23% 0.14
Grade 2 or higher complication in first year 86 19% 61 22% 25 14% 0.04
Grade 3 or higher complication in first year 2 0% 2 1% 0 0% 0.53
Recipient death 77 17% 50 18% 27 15% 0.49
Recipient graft failure 114 25% 73 26% 41 23% 0.51
Recipient diagnosis†
HCV/HCC 204 45% 115 41% 89 51% 0.05
Alcohol-related liver disease 52 11% 34 12% 18 10% 0.53
Cholestatic cirrhosis 130 29% 84 30% 46 26% 0.37
Other diagnosis 222 49% 144 51% 78 44% 0.14
*The t test was used for continuous variables, and the chi-square test or Fisher’s exact test was used for categorical varia-
bles. The tests were used to compare subjects at centers with <80% follow-up and subjects at centers with 80% follow-
up.
†Recipients could have more than 1 diagnosis, so the percentages may not add up to 100.
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As stated previously, donors were expected to attend
in-person clinic visits at postdonation times specified
by the protocol; any follow-up with the donor, includ-
ing phone contact, was considered completed follow-
up in this analysis. Donors could enroll at any time
before or after donation, so the number of expected
visits varied by donor because of the differing entry
and exit points in the study. Donors had an average
of 3.52 completed visits and 4.45 expected visits
(mean579%) during the time that they were enrolled
in the study (interquartile range for both completed
and expected visits53-5; Table 3). Donors with
expected visits in the first year after donation
(n5283) had on average 3.35 completed visits and
3.56 expected visits (mean594%, interquartile range
for both53-4). In postdonation years 2 to 4, 5 to 7,
and 8 to 10, the average numbers of completed visits
and expected visits per donor were 1.31 and 1.97
(mean566%), 1.42 and 2.16 (mean564%), and 0.96
and 1.80 (mean551%), respectively.
TABLE 2. QOL Data for Donors Who Donated at Centers With <80% or 80% Follow-Up
Overall (n5456)
<80% Follow-Up
(n5280)
80% Follow-Up
(n5176)
n or
Mean
% or SD
(Range)
n or
Mean
% or SD
(Range)
n or
Mean
% or SD
(Range) P Value*
Subjects with eligible
SF-36 forms†
265 58% 151 54% 114 65% 0.02
Average number of SF-36
forms per donor
1.8 1.0 (1-4) 1.5 0.8 (1-4) 2.2 1.1 (1-4) <0.001
Average PCS‡ 54.1 7.7 (21-70) 54.1 6.8 (23-63) 54.2 8.4 (21-70) 0.92
Average MCS‡ 52.0 9.5 (21 to 68) 52.6 8.9 (12-64) 51.4 10.0 (21 to 68) 0.15
*The t test was used for continuous variables, and the chi-square test or Fisher’s exact test was used for categorical varia-
bles. The tests were used to compare subjects at centers with <80% follow-up and subjects at centers with 80% follow-
up.
†Eligible SF-36 forms included forms completed at postdonation visits when the subject had at least 1 more expected post-
donation visit after the visit during which the SF-36 form was completed.
‡The scores have been normalized to the US population mean and SD (50 and 10, respectively).
TABLE 3. Distribution of Expected Visits and Completed Follow-Up
Mean per Subject SD 25th Percentile 75th Percentile
Overall (n5456 donors)
Expected visits 4.45 1.43 3.00 5.00
Completed follow-up visits 3.52 1.63 3.00 5.00
Mean of expected donor follow-up completed 79% 26% 60% 100%
Through year 1 (n5283 donors)*
Expected visits 3.56 0.79 3.00 4.00
Completed follow-up visits 3.35 0.88 3.00 4.00
Mean of expected donor follow-up completed 94% 14% 100% 100%
Years 2-4 (n5239 donors)*
Expected visits 1.97 0.83 1.00 3.00
Completed follow-up visits 1.31 0.94 1.00 2.00
Mean of expected donor follow-up completed 66% 40% 33% 100%
Years 5-7 (n5180 donors)*
Expected visits 2.16 0.82 1.00 3.00
Completed follow-up visits 1.42 1.02 1.00 2.00
Mean of expected donor follow-up completed 64% 39% 33% 100%
Years 8-10 (n589 donors)*
Expected visits 1.80 0.81 1.00 2.00
Completed follow-up visits 0.96 0.95 0.00 2.00
Mean of expected donor follow-up completed 51% 45% 0% 100%
NOTE: Donors could consent at any time after donation, so the number of expected visits within a year for a given donor
did not necessarily equal the total number of possible expected protocol study visits within that same year.
*Number of donors who had at least 1 expected visit within the given time range.
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Completed follow-up occurred for more than 90% of
the protocol study visits in the first several months
after donation, and then this dropped to 83% at 1
year and 62% at 2 years after donation (Fig. 1). The
percentage of completed follow-up remained steady
between 57% and 72% until 7 years after donation
and then decreased steadily until 10 years after dona-
tion. Although there was some variability among the 9
centers, the trends were similar over time.
The overall percentage of completed follow-up (clinic
visits and other follow-up) varied greatly by center
and ranged from 57% to 97% (Fig. 2). The percentage
of completed clinic visits was less varied and ranged
from 57% to 77%. Centers with high and low follow-
up had similar proportions of completed in-clinic vis-
its up to year 2, after which high–follow-up centers
had slightly higher rates of in-clinic follow-up (Fig. 3).
The proportion of other follow-up rose between month
1 and year 2 for high–follow-up centers, and this com-
pensated for the decrease in in-clinic follow-up,
whereas for low–follow-up centers, the proportion of
other follow-up remained at approximately 5% for the
duration of the study. Differences in the use of long-
distance visits made the biggest contribution to center
variability in achieving donor follow-up. The high–
follow-up centers were able to increase their propor-
tion of follow-up achieved by 10% to 30% through the
use of other methods of follow-up.
Predictors of completed follow-up in the first year
(corresponding to study time points at month 1, month
3, and year 1 after donation) included the following:
race, diagnosis of HCV or HCC, indicators for months
since donation, and transplant center (Table 4).
Donors of white race were more likely to complete their
follow-up during this early time period [odds ratio
(OR)53.27, 95% confidence interval (CI)51.25-8.58],
whereas donors whose recipients had diagnoses of
either HCV or HCC were less likely to complete follow-
up (OR50.34, 95% CI50.17-0.69). Donors were more
likely to complete their follow-up in the first and third
months after donation in comparison with the first
year after donation, and the follow-up during this early
time period varied by center (Table 4). Centers with
higher living donor volumes (in the absence of trans-
plant center indicators) had a significantly lower prob-
ability of completed follow-up (OR per 10-case higher
volume50.31, 95% CI50.15-0.66). For the centers
for which the information was available, there was no
statistical evidence that a clinical standard of requiring
follow-up beyond 1 month resulted in donors being
more likely to return for follow-up. These estimates
Figure 1. Overall proportion of donors with completed follow-up
among those with expected follow-up by time point (solid line)
with 61 standard error bars. The proportions of donors with
completed follow-up by center (dashed or dotted lines) are also
shown for the 9 A2ALL centers (labeled A-I) at time points with
at least 5 expected visits. The time points after donation were
week 1 (W1), month 1 (M1), month 3 (M3), and years 1 to 10
(Y1-Y10).
Figure 2. Proportions of expected follow-up achieved via clinic
visits and other follow-up methods by center for all time points
combined. Other follow-up included contact with donors via
phone, e-mail, post mail, or local laboratory testing. Centers are
ordered by the total living donor volume (descending) for 1998-
2010.
Figure 3. Percentages of in-person follow-up (top lines) and
other follow-up (eg, phone or e-mail; bottom lines) by groups of
centers that averaged <80% of expected follow-up (gray lines)
and centers that averaged 80% of expected follow-up (black
lines). The time points after donation were week 1 (W1), month 1
(M1), month 3 (M3), and years 1 to 10 (Y1-Y10).
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remained largely unchanged when prior recipient
death and retransplantation were added to the model.
Although not significant, prior recipient death and
retransplantation were associated with a higher proba-
bility of completed follow-up (OR for death51.33, 95%
CI50.44-3.97; OR for retransplantation52.29, 95%
CI50.46-11.46). The results were similar when recipi-
ent graft failure (defined as the first of death or retrans-
plantation) was included in the model (OR51.74, 95%
CI50.64-4.70).
Predictors of completed follow-up beyond the first
year included the following: age at donation,
TABLE 4. Probability of Completed Follow-Up in the First Year Modeled With Repeated Measures Logistic Regression
Predictor OR
Lower 95%
Confidence Limit
Upper 95%
Confidence Limit P Value
White race* 3.27 1.25 8.58 0.02
Recipient diagnosis of HCV or HCC† 0.34 0.17 0.69 0.003
Time after donation‡
Month 1 9.23 4.21 20.24 <0.001
Month 3 4.84 2.55 9.16 <0.001
Center§
A/H 3.31 1.05 10.45 0.04
B 0.21 0.11 0.40 <0.001
C 1.26 0.54 2.95 0.59
D 0.88 0.35 2.24 0.79
E 1.73 0.57 5.29 0.33
F 1.36 0.23 8.13 0.73
G 0.55 0.20 1.54 0.25
*The reference is nonwhite race.
†The reference is all other diagnoses.
‡The reference is year 1.
§One center was excluded from this model because it did not have any new donors during the prospective era. The refer-
ence was the overall mean.
TABLE 5. Probability of Completed Follow-Up in Years 2 to 10 Modeled With Repeated Measures Logistic Regression
Predictor OR
Lower 95%
Confidence Limit
Upper 95%
Confidence Limit P Value
Donor age at donation per 10 years 1.20 1.02 1.41 0.03
Year after donation*
3 1.42 0.88 2.30 0.15
4 1.13 0.68 1.88 0.63
5 1.11 0.65 1.90 0.69
6 0.93 0.55 1.57 0.79
7 0.47 0.28 0.80 0.005
8 0.48 0.27 0.86 0.01
9 0.39 0.20 0.77 0.006
10 0.24 0.10 0.59 0.002
Center†
A 0.69 0.45 1.05 0.08
B 0.29 0.17 0.47 <0.001
C 1.76 1.19 2.60 0.005
D 1.13 0.71 1.78 0.61
E 0.80 0.50 1.30 0.37
F 10.11 3.19 32.00 <0.001
G 0.49 0.27 0.89 0.02
H 0.77 0.55 1.08 0.13
I 0.84 0.60 1.17 0.31
*The reference is year 2.
†The reference is the overall mean.
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indicators for the number of years after donation, and
transplant center (Table 5). Older donors were more
likely to complete follow-up (OR per 10 years51.20,
95% CI51.02-1.41). The probabilities of completed
follow-up in the third, fourth, and fifth years after
donation were similar to the probability in the second
year, but from the sixth year on, follow-up became
less and less likely. Again, completed follow-up varied
greatly by transplant center (OR range50.29-10.11
versus the overall mean). In contrast to follow-up in
the first year, however, the center living donor volume
was not significantly associated with completed
follow-up when it was tested in the absence of center
indicators (OR per 10-case higher volume50.86, 95%
CI50.64-1.17). An indicator for whether the center’s
clinical standard required follow-up beyond 2 years
was also tested, and again, no relationship was shown
between this clinical standard and higher rates of
follow-up. Similarly to the early postdonation analy-
sis, the addition of prior recipient death and retrans-
plantation did not substantively change the estimates.
Recipient death was associated with no change in the
probability of completed follow-up (OR51.00, 95%
CI50.60-1.66), and recipient retransplantation was
associated with a nonsignificantly higher probability
of completed follow-up (OR51.44, 95% CI50.84-
2.49). The results were also similar for recipient graft
failure (OR51.10, 95% CI50.73-1.67).
Because center effects were highly significant in both
early and late time point models, we investigated the
amount of variation explained by center effects in com-
parison with other variables separately by time point in
logistic models for 3 months, 1 year, and 2 years. In the
3-month model, the generalized R2 values with and
without center effects were 0.07 and 0.05, respectively.
The corresponding values at the 1-year time point were
0.13 and 0.03, and for the 2-year time point, they were
0.22 and 0.02. These results demonstrated an increas-
ing effect of individual center practice as the time from
donation increased. By 2 years, center effects were 10-
fold the effect of all other covariates.
Because A2ALL was an observational study, we
postulated that center variation in donor follow-up
might be related to differences in the standard of care
for the follow-up of non-A2ALL donors. Although all
centers and donors agreed to follow the A2ALL proto-
col, the degree of rigor and resources used to achieve
donor follow-up might have varied according to each
center’s standard of care. Thus, the centers were sur-
veyed to determine their standard of care for long-
term donor follow-up, and 7 centers responded. Fig-
ure 4 also demonstrates that center practice differed
in how long donors were expected to return to the
clinic, with 1 center expecting drop-off after the first
week and others expecting donors to return as long as
10 years after donation. Although the highest per-
forming center (center F) expected annual follow-up
as part of its clinical standard of care through 10
years after donation, even centers whose standard of
care did not follow donors beyond 2 years were able
to achieve approximately 80% overall follow-up in the
A2ALL study. Thus, standard-of-care practices did
not fully explain the center variability in A2ALL
follow-up success.
For the subset of 265 donors who completed at least
1 SF-36 form after donation and had a subsequent
expected visit, the PCS and the MCS from the SF-36
were tested as potential predictors of completed follow-
up. These donors had a total of 475 forms (average per
donor51.8, range51-4; Table 2). The average PCS
and MCS values for this subset of postdonation forms
were 54.1 (range521-70) and 52.0 (range521 to 68),
respectively, with higher scores indicating better func-
tioning. Although the ranges were wide, the means
were higher than the general population mean of 50
but were within 1 SD (SD510). A higher PCS was mar-
ginally associated with a lower probability of completed
follow-up (OR per 10-unit increase or 1-SD increase in
a normative population50.74, 95% CI50.55-1.00).
No significant associations between completed follow-
up and MCS were found (OR per 10-unit increase or 1-
SD increase in a normative population50.99, 95%
CI50.79-1.23).
DISCUSSION
In summary, living liver donors were very compliant
with follow-up for the first year, but follow-up
decreased over time in a nonlinear manner. From years
2 to 7, the proportion of completed visits was approxi-
mately 70%. There were substantial center differences
in completed visits. Although every center agreed to fol-
low the A2ALL protocol, which required annual donor
visits to the transplant center, the standard clinical
protocol for donor follow-up at each center varied, par-
ticularly after the first year. Additionally, centers varied
in their use of methods for obtaining information indi-
rectly (ie, telephone and distant visits outside the
transplant center).
Figure 4. Anticipated follow-up based on usual clinical practice
as reported by centers. There were 9 A2ALL centers, but data
were not available for 2 centers that were no longer participating
in the study at the time of the analysis. The time points after
donation were week 1 (W1), month 1 (M1), month 3 (M3), and
years 1 to 10 (Y1-Y10).
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Patients who missed follow-up did not differ in
many ways from those who completed follow-up, and
this argues against a substantial systemic bias in the
analysis of long-term donor outcomes for those who
followed up. However, there were some differences.
Donors who missed follow-up in the long-term were
more likely to be younger and have a higher PCS on
the SF-36. This suggests that donors may be less
likely to follow up if they are healthier and do not per-
ceive a need for care. This suggests that data gathered
for donors who do follow up will lead to a lower
HRQOL than that of the overall target population of
all donors, and this is reassuring. Nonwhite race also
predicted lower rates of completed follow-up because
whites were more than 3 times more likely to follow
up during the first year after donation. Although we
did not collect socioeconomic data, this may highlight
potential economic or cultural barriers to follow-up.
The distance from the transplant center could not be
calculated because we collected only the state of resi-
dence as a variable. When this was analyzed as the
same state or a contiguous state versus more than 1
state from the transplant center, it was not predictive
of follow-up. However, distances between states vary
widely in the different areas between the A2ALL cen-
ters; thus, the actual distance may be an unmeasured
factor included in the center differences measured. A
recipient diagnosis of HCV or HCC also predicted
lower rates of follow-up with an OR of 0.34. The rea-
sons for these 3-fold lower odds of donor follow-up
are unclear. Although recipient complications and
adverse outcomes did not predict follow-up, the recip-
ient diagnosis may be a marker for higher rates of
complications due to recurrence in HCV and HCC
patients or other unmeasured factors. This phenom-
enon needs further exploration.
Our data concur with prior data suggesting that
quality of life (QOL) is at or above US norms on a gen-
eral QOL survey11 and that virtually all are satisfied
with their decision to donate, regardless of recipient
outcomes.9,10 Severe psychiatric disturbances have
been reported in some living donors from our group,
however, and this suggests that ongoing long-term fol-
low-up is needed.15 Interestingly, centers that
achieved 80% follow-up had donors who were on
average younger and had fewer higher grade compli-
cations (Tables 1 and 2); these are all factors associ-
ated in individual donors with a lower probability of
follow-up (Tables 4 and 5). This suggests that some
centers are able to overcome the barriers to follow-up
and achieve higher rates of long-term follow-up
despite covariate mixes that would suggest the oppo-
site. This deserves further investigation.
Our data are limited by the fact that we cannot
attribute the reasons for the lack of donor follow-up
convincingly. Although centers had agreed to pursue
follow-up through the study, there was intercenter
and intracenter variability. It is also not possible to
derive the reason for the lack of follow-up without
contact with those donors (perhaps by an outside
party, eg, UNOS) to assess these reasons. Despite
these limitations, quantifying the proportion of donor
follow-up is important for understanding our limita-
tions in assessing long-term donor outcomes. This
was a National Institutes of Health–funded study, so
it is likely that our efforts at donor follow-up exceeded
what is currently achievable without a change in
incentives at the transplant center level or without
centralized follow-up by OPTN or the Department of
Health and Human Services. However, the ability of
some centers to achieve nearly complete donor follow-
up (97%) demonstrates that the adoption of best prac-
tices can improve donor follow-up and that 80% can
be achieved as suggested in the UNOS guidance docu-
ment17 with a combination of motivating donors less
likely to follow up (younger, healthier donors) and
using the telephone (or other long-distance contact) in
addition to clinic visits. Although it is likely that phys-
ical follow-up at the transplant center provides more
valuable information than phone contact, any contact
and particularly QOL data are useful and should be
encouraged. It is important to note that there was
nearly a 1.5-fold range in physical visits between cen-
ters in addition to the nearly 2-fold range in follow-up
when phone contact was included. With increased
reliability on telemedicine and social networking, this
represents a significant opportunity to gain valuable
information about long-term donor outcomes and
should be included in future research and in OPTN
policy. It is important to note that no centers achieved
80% follow-up with actual physical clinic visits alone
after the first year after donation.
In summary, these data suggest that donor follow-
up is excellent in the short run and declines over
time. A large portion of the variability in donor follow-
up is related to center differences and could be
improved by protocols for long-distance donor follow-
up, including phone contact, cooperation with pri-
mary care providers, and perhaps a telemedicine ini-
tiative. The fact that donors who missed follow-up
visits were more likely to have higher physical QOL
and to be younger reassures us that we may not be
missing substantial complications. However, longer
follow-up and improved center protocols for that
follow-up are clearly needed to improve our knowledge
of long-term complications after donation and to
ensure the long-term health of those donors. Future
research should also compare the quality of the data
and the value of long-distance initiatives versus phys-
ical returns to the transplant sites in order to improve
the quality of follow-up and decrease the burden on
donors and centers.
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